NCT00487942

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Cephalon · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	armodafinil	50 mg/day armodafinil
DRUG	armodafinil	100 mg/day armodafinil
DRUG	armodafinil	200 mg/day armodafinil
DRUG	placebo	placebo

Timeline

• Start date: 2007-07-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2007-06-19
• Last updated: 2013-07-19
• Results posted: 2010-12-20

Locations

12 sites across 1 country: United States